Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Evgen Pharma "very busy" at start of "exciting year"

Evgen Pharma PLC

Evgen Pharma PLC (AIM:EVG) CEO Dr Huw Jones speaks to Proactive from the sidelines of the BIO International Convention in Boston, MA, following the release of final results for the year to 31st March 2023. Dr Jones gives his take on how the business performed over the twelve months, before moving on to talk about what the current year has in store. He says the clinical stage drug development company is "very busy" at the start of an "exciting year." He also thanks outgoing chief financial officer Richard Moulsen for his contribution to the company. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

June 08, 2023 04:13 AM Eastern Daylight Time

Video

PathPresenter Empowers Biorepositories to Share Pathology Imaging Data for Biomedical Research

PathPresenter

PathPresenter, the global image sharing platform for pathology, announced today a new enterprise workflow platform that empowers biorepositories and databanks to share imaging data with other institutions, AI companies, pharma, and industry for biomedical research. The scalable and secure cloud-based platform makes the imaging data easily available to researchers and provides smart tools to maximize collaborative research for the ultimate benefit of patients and donors. By adopting the PathPresenter platform, biorepositories and organizations have a unique opportunity to generate a return on investment for their digital pathology infrastructure. Watch a video overview of the new research platform by PathPresenter founder, Dr. Rajendra Singh, here. Biorepositories play a crucial role in the collection, storage, and delivery of high-quality biospecimens to researchers, while providing honest brokerage services for de-identification of these biospecimens. This facilitates the sharing of knowledge among institutions and promotes meaningful translational biomedical research. The emergence of digital pathology has opened new possibilities for leveraging biorepositories by enabling the sharing of imaging data for research purposes. With the growing use of digital slides in research, these data banks play a vital role in data distribution. However, there has been a lack of well-established, standardized workflows that facilitate the easy distribution of data, collaboration among researchers, and user-friendly tools for working with whole slide images in research. PathPresenter’s scalable and secure cloud-based digital workflow platform empowers biorepositories to establish next generation repositories of whole slide images. Managed by the organization, PathPresenter allows biorepositories to upload whole slide images along with de-identified tissue metadata such as diagnosis, tumor grade, treatment information, and outcome data. It then provides administrative tools that enable researchers from anywhere in the world to register for access. Once vetted and approved by the organization, research users can search and utilize the data stored in the repository. The platform provides powerful search capabilities that allow researchers to enter specific criteria to find relevant datasets for their research. The data can be downloaded or aggregated in private folders for online research, including the ability to define regions of interest, add annotations, incorporate metadata, and even deploy AI modules. PathPresenter offers features to manage user roles and permissions, such as viewing, editing, or deleting annotations, as well as tools to audit annotator progress. Researchers can build entire research projects on the PathPresenter platform, as well as test AI models without exhausting limited biospecimens. An early adopter of the PathPresenter research platform was the Food and Drug Administration (FDA) which used it to centralize the collection of tumor infiltrating lymphocytes in breast adenocarcinoma for the validation of de-novo AI technologies. For more information see here: https://www.fda.gov/media/148912/download. Recently, the Midwestern division of the Cooperative Human Tissue Network (CHTN) and PathPresenter have collaborated to establish an innovative tissue repository. The main goal of this collaborative project is to build an elastic compute cloud-based infrastructure and scalable workflows, ensuring easy accessibility of data to researchers. Additionally, the project aims to provide intelligent tools that enhance collaborative research, with the ultimate objective of utilizing the data to benefit patients and donors. “The biobank of the future requires not only the collection and timely delivery of high quality biospecimens for researchers, but also simultaneous annotation and de-identification of these biospecimens that can be easily accessible to the research community,” said Dr. Anil Parwani, Principal Investigator for the Midwestern division of CHTN. “We chose PathPresenter as our workflow platform due to a combination of factors, including the tried and tested nature of the viewer, its cloud-based infrastructure to enable easy scaling, tools to centralize collection of annotations and sharing of images, embedded AI that can be released to members as needed, and the flexibility of the platform for customization to the needs of CHTN.” “PathPresenter has always been focused on creating efficiencies and value for pathology departments/organizations and truly becoming the center of personalized care for our patients,” added Dr. Rajendra Singh, co-founder of PathPresenter. “Our ‘smart’ data distribution workflow is another step in the same direction that will allow biorepositories hosted by pathology departments to securely share data with multiple researchers and help enhance research.” About PathPresenter PathPresenter is the global image sharing platform for pathology. We are on a mission to help democratize access to the world’s pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded in 2017 by dermatopathologist and digital pathology innovator, Dr. Rajendra Singh, PathPresenter has been adopted by 30+ tier one medical institutions for clinical care, education, and research, and has built a thriving community of 50,000+ users in 172 countries to easily view and share digital pathology images and knowledge. Learn more about pathpresenter.com. Contact Details PathPresenter Cory Batenchuk - SVP of Operations +1 873-355-9913 cory@pathpresenter.com About PathPresenter PathPresenter is the global image sharing platform for pathology. We are on a mission to democratize access to the world’s pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded in 2017 by dermatopathologist and digital pathology pioneer, Dr. Rajendra Singh, PathPresenter has been adopted by 30+ tier one medical institutions for clinical care, education, and research, and has built a thriving community of 50,000+ users in 172 countries to easily view and share digital pathology images and knowledge. For more information visit www.pathpresenter.com. Contact Details Cory Batenchuk +1 873-355-9913 cory@pathpresenter.com Company Website https://pathpresenter.com

June 07, 2023 10:00 AM Eastern Daylight Time

Voyageur Pharmaceuticals with a "big market to go for"

Voyageur Pharmaceuticals Ltd

Proactive research analyst John Savin speaks to Thomas Warner after publishing a new research note on Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF), a Canadian company that specialises in transforming raw materials into pharmaceutical-grade contrast agents that can be used in medical imaging. Savin gives a brief summary of the note, titled "Voyageur Pharmaceuticals: Earthly profits from contrasting media." Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

June 07, 2023 08:00 AM Eastern Daylight Time

Video

News Release

MustGrow partners with Bio Ag Product Strategies to enhance soil health technologies

MustGrow Biologics Corp.

MustGrow CEO Colin Bletsky joins Natalie Stoberman from the Proactive studio to share details of its new agreement with Bio Ag Product Strategies for the development of technologies related to soil microbiome and soil health. Bletsky says the agreement with Bio Ag Product Strategies will facilitate development, pre-marketing activities, and commercialization plans to showcase the benefits of MustGrow's technology to growers. This includes MustGrow's portfolio of organic products that feed the soil microbiome, benefiting yield, water usage, fertility, and plant health. Bletsky adds that this partnership can allow MustGrow to conduct large-scale farm trials, position their products in high-value fruit and vegetable markets across the United States, and gain registrations for their bio soil amendment product in each state. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

June 06, 2023 01:46 PM Eastern Daylight Time

Video

AmeriLife’s Saybrus Partners Agrees to Transfer Agreement with Prudential Financial to Expand Firm’s Industry-Leading Life Distribution

AmeriLife

Saybrus Partners (“Saybrus”), a market leader in life and annuity distribution and an affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has reached an agreement with Prudential Financial, Inc. (“Prudential”) to move the latter’s wholesale life insurance brokerage general agency known as Prudential Life Distributors to Saybrus, cementing the firm as a premier provider of life insurance point of sale consultation in the industry. Per the agreement, terms of the deal were not disclosed. “We’re thrilled to welcome our newest colleagues to Saybrus and are excited for the opportunities ahead,” said Edward W. Cassidy, managing principal of Saybrus Partners. “Today’s announcement represents a significant milestone for our company and highlights the strength of our best-in-class life insurance distribution model. We look forward to continuing to grow our business and accelerating the success of our partners’ advisors and their clients.” “We are thrilled to partner with Saybrus, who shares our deep commitment towards clients and the people who support them,” added Kevin Brayton, head of Individual Life Insurance Distribution and Sales for Prudential Financial. “I am confident that under Ed’s leadership, Saybrus will only continue to drive a much greater impact on key relationships and strengthen the value of those relationships over time.” Based in Hartford, Conn., Saybrus Partners was formed in 2009 to bring its boutique distribution model to financial institutions, delivering customized support, proactive consultation and transparent, centralized management for advisors and insurance agents. The company was acquired by AmeriLife in 2021 and operates as a standalone company. Since its inception, Saybrus, which has nearly 200 employees nationwide, has insured nearly half a million lives with more than $130 billion death benefit in force. “As AmeriLife Wealth sets out to redefine the agent and advisor experience, today’s announcement is a testament to the incredible impact that our distribution partners are making,” said Mike Vietri, Chief Distribution Officer of Wealth for AmeriLife. “We’re excited for this injection of talent into an already performative business, and look forward to continued expansion of our services and support for the institutional market.” ### About Saybrus Partners Saybrus Partners, LLC helps institutions and financial professionals address clients' needs with insurance and annuity solutions for basic protection as well as retirement, estate and business planning. Its partner firms include institutional financial advisories, insurance retailers, banks and broker/dealers. Customizing its services to best fit its partners' businesses, the company offers a complete set of distribution capabilities including assisted sales, traditional wholesaling, new business operations and custom product design. For more information, visit www.saybruspartners.com and follow Saybrus on LinkedIn. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Distribution Inquiries Aziz Ali +1 806-490-9853 aali@saybruspartners.com Company Website https://amerilife.com/

June 06, 2023 10:00 AM Eastern Daylight Time

ARCHCARE SENIOR LIFE PACE PROGRAM PARTNERS WITH INTUS CARE TO DELIVER A DATA DRIVEN APPROACH TO EXCEPTIONAL ELDER CARE

Intus Care

ArchCare, the Archdiocese of New York’s healthcare system that every day cares for more than 10,000 seniors, the poor, and persons with special needs, in partnership with Intus Care, developer of innovative predictive software and services designed for geriatric health, has recently implemented data-driven software that more accurately identifies high-risk elders in its ArchCare Senior Life, Program of All-inclusive Care for the Elderly (PACE). ArchCare will utilize Intus Care’s Integrated Care Services and its software analytics platform to allow ArchCare caregivers to mount an immediate, aggressive response. ArchCare Senior Life, Program of All-inclusive Care for the Elderly (PACE), is a comprehensive and innovative model of care for people 55 years of age and older who qualify for nursing-home-level care. PACE is a government Medicare and Medicaid program designed to support older Americans who wish to remain living in their homes by providing comprehensive medical and social services, including medical management, transportation, and assistance with daily activities. ArchCare leverages advanced technologies to serve its population of residents and participants across its system of nursing homes and PACE centers. ArchCare will utilize Intus Care’s Integrated Care Services and its software analytics platform to optimize the care provided to adults enrolled in ArchCare Senior Life, which serves elders in Manhattan, The Bronx, Staten Island, and Westchester. Intus Care is a developer of innovative predictive software and services designed for geriatric health. “With this new technology, we can pinpoint who is at risk for a decline, fall or other adverse event, and focus care where it’s needed immediately," said Dr. Walid Michelen, Senior Vice President, Clinical Planning & Innovation and Chief Medical Officer, ArchCare. “Intus Care’s Integrated Care Services tool helps us ensure that ArchCare’s PACE participants are receiving the most effective care and support to enhance their quality of life." By utilizing comprehensive, duals-specific algorithms, Intus Care identifies participants at high risk for hospitalizations and chronic disease onset - allowing ArchCare’s PACE program to optimize care planning. Intus Care has a team of PACE experts committed to helping geriatric care programs grow and improve their operations. Working collaboratively with leadership teams and staff, the ICS process executes project work plans, creates a data-driven culture to improve clinical outcomes, ensures CMS compliance, manages utilization, and optimizes quality. Over the last year, Intus Care has increased its presence in NYC with an office on East 78th Street, a growing employee base in the area, and the relocation of several leadership team members. “ArchCare is a forward-thinking PACE program in Manhattan, New York, with a fantastic team, providing hundreds of participants high-quality, individualized care as they age in place,” said Laura Ferrara, Chief Strategy Officer at Intus Care. “We are proud to work with ArchCare, empowering their team through data-driven decisions, optimizing care outcomes, operational practices, and compliance alignment across the program.” About ArchCare ArchCare is the Continuing Care Community of the Archdiocese of New York, and one of the nation’s largest and most dynamic Catholic healthcare systems. ArchCare provides quality care to thousands of people of all faiths through its home and community-based and residential care programs, including health plans and nursing home alternatives, adult day care, long-term skilled nursing care, short-term rehabilitation, home care, assisted living, hospice, an acute care specialty hospital and services for people with Huntington’s disease, HIV/AIDS, developmental disabilities, and other specialized care needs. About Intus Care Intus Care leverages analytics and data-driven services to improve care for the healthcare system’s most socially vulnerable and clinically complex patients. By integrating disparate data sources, highlighting patient risk, and implementing innovative processes, Intus Care empowers managed care organizations, including PACE programs and Special Needs Plans (SNPs), to make informed decisions and drive outcomes. Contact Details SVM Public Relations Jordan Bouclin & Alison Matthiessen +1 401-490-9700 intuscare@svmpr.com ArchCare Sarah McAllister +1 212-576-2700 Goodman.ArchCare@goodmanmedia.com Company Website https://www.intuscare.com/

June 06, 2023 10:00 AM Eastern Daylight Time

LiveSpo represents Vietnam, announces world's first spore probiotics in nasal spray form at the BIO International Convention

LiveSpo

HANOI, VIETNAM - Media OutReach - 6 June 2023 - LiveSpo is the first representative from Vietnam to participate in the BIO International Convention, an exhibition showcasing breakthrough biotechnology solutions, held in Boston, USA. This demonstrates remarkable development of the Vietnamese pharmaceutical sector in the realm of biotechnology. The BIO International Convention, held annually in the United States in June, attracts approximately 14,000 attendees from 65 countries. It serves as a platform for biopharmaceutical companies, investors, and government leaders to exchange ideas, present research findings, and explore partnership opportunities in the field. This year, the convention takes place from June 5 to 8 at the Boston Convention & Exhibition Center in Massachusetts, USA. Among the 1,200 booths, LiveSpo Pharma proudly represents Vietnam as the sole participant, introducing "Made in Vietnam" spore probiotics technology for respiratory disease treatment. Dr. Nguyen Hoa Anh, R&D Director and Chairman of LiveSpo Pharma, will present LiveSpo's breakthrough spore probiotics technology at the BIO International Convention 2023. This technology features liquid-form, multi-strain, high-concentration probiotics, including the flagship product LiveSpo NAVAX, a pre-active SPL spore probiotic delivered in the form of nasal spray. After undergoing rigorous clinical trials aligned with US standards, LiveSpo NAVAX has emerged as the world's first spore probiotic nasal spray. Its significant impact on reducing treatment duration for acute respiratory infections in children has been proven. LiveSpo NAVAX demonstrates an exceptional ability to reduce the load of Respiratory Syncytial Virus (RSV) by 600-fold and influenza virus by 900-fold. The safety and remarkable efficacy of this product have been published in the esteemed Scientific Reports journal (Nature), and the article ranked among the top 100 most downloaded in 2022. (Reference: https://www.nature.com/articles/s41598-022-16136-z ) The presence of LiveSpo NAVAX at the BIO International Convention 2023 signifies the leapfrog development of Vietnamese science in the probiotics industry, particularly spore probiotics technology, which has gained traction as a healthcare trend worldwide. Moreover, it offers an opportunity to promote breakthrough "Made in Vietnam" technology globally, providing safe and sustainable treatment options to more patients, particularly children. LiveSpo NAVAX addresses the treatment needs of 80 percent of children under two years old infected with RSV, a condition currently lacking a cure. It also presents a path towards "A Future Without Antibiotics", mitigating the persistent global health concern of antibiotic overuse. During the BIO International Convention, LiveSpo Pharma will engage in B2B meetings with partners from various countries, including Turkey, the UK, Canada, Spain, Australia, Brazil, India, France, and others. Discussions will revolve around the potential and practical applications of breakthrough spore probiotics, as well as opportunities for exclusive distribution of LiveSpo products in international markets. The Vietnamese representative will also host a booth and participate in thematic seminars to explore and remain updated on scientific and technological advancements in developed countries. Dang Quoc Hung, CEO/Managing Director of LiveSpo, expressed excitement about the opportunity to join the BIO International Convention 2023, stating, "Participating in the world's leading exhibition of breakthrough biotechnology solutions testifies to LiveSpo's readiness and competitiveness in the global pharmaceutical market. This milestone serves as a stepping stone towards realizing our vision of introducing Vietnamese biotechnology and LiveSpo spore probiotics to more countries, showcasing Vietnam's capacity to produce products with high knowledge content." About BIO: BIO International Convention, which is organized by BIO, is the world’s largest gathering of leading investors and partners in the biotechnology industry.Founded in 1993, BIO is the world’s largest advocacy association representing member companies, research institutions, state biotechnology groups, and related organizations across the US and in over 30 countries. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products. About LiveSpo Pharma: LiveSpo is an R&D, manufacturing, and distribution brand of Spobiotics (probiotics in spore form) for digestive and respiratory health, leading in breakthrough technology, rapid effectiveness, and convenience, aiming for "A Future Without Antibiotics".LiveSpo has applied spore probiotics technology to develop breakthrough products in liquid form, multi-strain, and high concentration, pioneering in protecting and improving the community's health in a comprehensive, natural and effective way.LiveSpo's outstanding achievements:- Attended the 13th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health (IPC 2019) in Prague, Czech Republic.- The only Vietnamese representative on probiotics to attend the International Microbiology Conference 2022 (ASM 2022).- LiveSpo's clinical trial research is published in the Scientific Reports journal (the Nature): LiveSpo NAVAX supports the treatment of acute respiratory infections in children infected with RSV Effects of nasal-spraying LiveSpo NAVAX in treatment of acute respiratory infections in children Effects of LiveSpo CLAUSY and LiveSpo DIA 30 in treatment of persistent diarrhea in children Effects of LiveSpo X-SECRET in supporting treatment of sexually transmitted diseases Email: huong.md@livespo.com Contact Details (Ms) Mai Dieu Huong huong.md@livespo.com Company Website https://livespo.com/en/

June 06, 2023 09:31 AM Eastern Daylight Time

Image

Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study

Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to provide an update on subsidiary Algernon NeuroScience successfully completing the highest planned single dose of its escalating Phase 1 clinical study of an intravenous formulation of AP-188 or DMT. The company is looking to investigate DMT for treatment of stroke and traumatic brain injury. Moreau telling Proactive the committee tasked with reviewing the program has confirmed that there were no safety or tolerability issues with the highest dose, which was able to maintain plasma DMT concentrations at targeted levels and which was below the established psychedelic dose. The company says the second part of the study will include dosing subjects for 6 hours with repeated administrations over a two-week period which can be used in its first Phase 2 study for stroke and TBI. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

June 05, 2023 01:43 PM Eastern Daylight Time

Video

News Release

BioHarvest Sciences 1Q financials show continued growth with a 209% year-over-year increase

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share news the company has released first-quarter 2023 financial numbers that show big gains over 2022. The company saw VINIA revenues growing 209% compared to 1Q 2022, reaching $2.2 million. Sobel also shared with Proactive the company saw gross margins increase to 37%, from 26% a year earlier. The company is sticking with its guidance of year-over-year revenue growing three times to over $17 million. BioHarvest is looking to be cash flow break-even in 4Q 2023. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

June 02, 2023 12:17 PM Eastern Daylight Time

Video

1 ... 119 120 121 122 123 ... 309